Integrated BioTherapeutics Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013985)
◆英語タイトル:Integrated BioTherapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013985
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Integrated BioTherapeutics Inc (IBT) is a biotechnology company that discovers novel vaccines and therapeutics for infectious diseases. The company’s products include polyclonal and monoclonal antibodies raised against various emerging pathogens, vaccines and therapeutics against bacteria, pan-filovirus antibody candidates, vaccines and a variety of other product candidates for antiviral diseases. It also provides research and development service such as antiviral testing, vaccine immunogenicity and efficacy testing, animal model testing, assay development, cytokine and biomarker analysis, and antibiotic testing services. IBT’s vaccines and antibody therapeutics are used in the treatment of Filoviruses Ebola, Sudan, Hemorrhagic fevers, Marbur, Equine Encephalitis viruses and Chikungunya and Hepatitis C. The company partners with biotechnology, pharmaceutical, and academic laboratories. IBT is headquartered in Rockville, Maryland, the US.

Integrated BioTherapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Integrated BioTherapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Integral Molecular and Integrated BioTherapeutics Enter into Agreement 11
Agilvax Enters into Co-Development Agreement with Integrated BioTherapeutics 12
Licensing Agreements 13
Integrated BioTherapeutics Enters into Licensing Agreement with ExpreS2ion Biotech 13
Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 14
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon 15
Integrated BioTherapeutics Inc – Key Competitors 16
Integrated BioTherapeutics Inc – Key Employees 17
Integrated BioTherapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product News 19
05/18/2017: Immunization elicited Antibody shows Universal Protection against Multiple Ebola viruses 19
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Integrated BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Integrated BioTherapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Integrated BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Integral Molecular and Integrated BioTherapeutics Enter into Agreement 11
Agilvax Enters into Co-Development Agreement with Integrated BioTherapeutics 12
Integrated BioTherapeutics Enters into Licensing Agreement with ExpreS2ion Biotech 13
Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 14
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon 15
Integrated BioTherapeutics Inc, Key Competitors 16
Integrated BioTherapeutics Inc, Key Employees 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Integrated BioTherapeutics Inc-製薬・医療分野:企業M&A・提携分析(Integrated BioTherapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆